Biomolecular Structure Analysis to Accelerate Develoment of New Vaccines and Monoclonal Antibodies
Manufacturing of consistently high quality products is the commitment of the pharmaceutical industry. To achieve this, new products must be thoroughly tested and the results meet government-approved product specifications. Improving existing and adopting improved analytical technologies for product testing ensure the production of safe and effective products. This is particularly critical for the manufacturing of biologic products which, relative to small molecular drugs, have a larger size, are more complex in structure and are thus more difficult to characterize. Modern instrumental analyses, including Mass Spectrometry, Nuclear Magnetic Resonance and Capillary Electrophoresis, are capable of high resolution and precision analyses of primary and higher order biomolecule structures. Using these cutting-edge technologies, we are proposing to develop new methodologies to improve biomolecule characterization. The proposed internships will provide training in these advanced technologies and thus foster the development of a talent pool of highly qualified Canadians with expertise to contribute to research-based biopharmaceutical industries.